Results 321 to 330 of about 2,285,924 (374)
Drug development in higher-risk myelodysplastic syndromes. [PDF]
Blood Cancer JVenugopal S, Sekeres MA.
europepmc +1 more source
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes. [PDF]
Front ImmunolWei Y +12 more
europepmc +1 more source
How we diagnose Myelodysplastic syndromes. [PDF]
Front OncolOster HS, Mittelman M.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Disease Primers, 2022
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li +4 more
semanticscholar +4 more sources
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li +4 more
semanticscholar +4 more sources
Annals of the New York Academy of Sciences, 2004
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela +7 more
+8 more sources
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela +7 more
+8 more sources
Hematology and Cell Therapy, 1996
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel +4 more
+9 more sources
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel +4 more
+9 more sources
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Journal of the American Medical Association (JAMA), 2022Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along with anemia, neutropenia, or thrombocytopenia.
M. Sekeres, Justin Taylor
semanticscholar +1 more source